Brokerages Set Evolent Health, Inc. (NYSE:EVH) Target Price at $21.92

Shares of Evolent Health, Inc. (NYSE:EVH) have been assigned an average recommendation of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $18.54.

EVH has been the topic of several research analyst reports. UBS Group decreased their price target on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. Oppenheimer lowered their price target on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday. Truist Financial reduced their price objective on Evolent Health from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. lowered their price objective on Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, November 22nd. Finally, Royal Bank of Canada reduced their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, January 14th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. R Squared Ltd bought a new position in Evolent Health in the 4th quarter valued at $31,000. Quarry LP bought a new position in shares of Evolent Health in the second quarter valued at about $32,000. Covestor Ltd grew its holdings in Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC increased its position in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after acquiring an additional 1,556 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Evolent Health in the second quarter worth about $61,000.

Evolent Health Trading Down 0.7 %

Shares of NYSE:EVH opened at $10.11 on Monday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The stock’s 50-day moving average is $11.45 and its 200-day moving average is $20.39. The company has a market cap of $1.18 billion, a P/E ratio of -11.10 and a beta of 1.45. Evolent Health has a 52-week low of $9.74 and a 52-week high of $35.00.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The business had revenue of $621.40 million during the quarter, compared to analyst estimates of $625.58 million. During the same period last year, the business earned $0.19 EPS. Equities research analysts predict that Evolent Health will post 0.26 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.